ysl

Tyroserleutide (YSL), a small molecular tripeptide isolated from porcine spleen degradation products, inhibits the growth and metastasis of human hepatocellular carcinoma (HCC) both in vitro and in vivo.

Cyslabdan inhibits the synthesis of Pentaglycine Interpeptide Bridge.

DSTYSLSSTLTLSK, a human peptide, facilitates the quantitative detection of Infliximab (Avakine), a chimeric monoclonal IgG1 antibody. Infliximab specifically targets and binds to TNF-α.

DSTYSLSSTLTLSK acetate is a human generic peptide that can be used for the quantitative detection of infliximab.

DSTYSLSSTLTLSK TFA, a generic human peptide, facilitates the quantitative detection of Infliximab (Avakine), a chimeric monoclonal IgG1 antibody targeting TNF-α, as indicated in study [1].

IRGRILHDGAYSLTLQGLGIH TFA, a multi-epitope class II rat HER2/neu peptide, is utilized in the study of class II HER2-DC1 vaccines [1].

IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2/neu peptide used in HER2-DC1 vaccine research studies [1].

Cyclopentenyl cytosine triphosphoric is an active intracellular metabolite of the antineoplastic nucleoside analogue cyclopentenyl cytosine (CPEC). It inhibits CTP synthase and depletes the cytidine nucleotide pool. Cyclopentenyl cytosine triphosphoric is used in cancer research, including studies on leukemia.

Gemilukast (ONO-6950) is an orally active and potent dual inhibitor of cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2), inhibits LTC 4-induced bronchoconstriction, and is inhibitory to human CysLT1 and CysLT2, and may be used in the treatment of asthma.

Pranlukast (ONO-1078) is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Montelukast sodium (MK0476) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Lycorine (Narcissine) inhibits protein synthesis and may inhibit ascorbic acid biosynthesis, although studies on the latter are controversial and inconclusive.

4-Hydroxyflavanone is a natural product, shows full vasorelaxing effects

LM-1484 displays a higher affinity for 3H-LTC4 sites and is an antagonist of CysLT1 receptor.

GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist (pEC50: 7.5). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis.

HAMI 3379 is a potent and selective antagonist of the Cysteinyl leukotriene (CysLT2) receptor. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury. It also attenuates microglia-related inflammation.

Montelukast (Singular) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Lysyllysyllysine is a cationic moiety. It may be used in the construction of gene delivery vectors and DNA nanoparticles.

ONO 2050297 (Compound 19) is a selective cysteinyl leukotriene (CysLT) antagonist, with IC50 values of 17 nM for CysLT1 and 0.87 nM for CysLT2. It is applicable for research in bronchial asthma.

KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.

Quininib is a selective antagonist of CysLTR1 and CysLTR2, with IC50 values of 1.2 and 52 μM, respectively, exhibiting anti-angiogenic and anti-tumour effects.

MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4′-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4′-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation.

Pentalysine is a peptide.

Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1.